secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0000078003-23-000081
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer restructures R&D, elevates Oncology as standalone unit; CDO William Pao departing Aug 15
--------------------------------------------------------------------------------

- Pfizer restructures R&D, making Oncology a standalone unit; Dr. Chris Boshoff becomes Chief Oncology R&D Officer, EVP.
- Dr. William Pao, Chief Development Officer, EVP, role eliminated; he will depart effective August 15, 2023.
- Severance includes one year base salary and target bonus, two years welfare benefits, vesting of sign-on awards.
- Reorganization driven by planned investment in Oncology, including proposed acquisition of Seagen Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/pfe-20230721.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer